Dennis Mulroy - 16 Dec 2025 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
16 Dec 2025
Net transactions value
-$503,733
Form type
4
Filing time
18 Dec 2025, 16:13:26 UTC
Previous filing
07 Jan 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MULROY DENNIS CHIEF FINANCIAL OFFICER C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO /s/ Eric Loumeau, Attorney-in-Fact 18 Dec 2025 0001276840

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $201,600 +10,000 +66% $20.16 25,126 16 Dec 2025 Direct F1
transaction ANAB Common Stock Sale $417,821 -9,365 -37% $44.62 15,761 16 Dec 2025 Direct F2, F3
transaction ANAB Common Stock Sale $287,511 -6,360 -40% $45.21 9,401 16 Dec 2025 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -10,000 -12% $0.000000 70,600 16 Dec 2025 Common Stock 10,000 $20.16 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects the acquisition of 1,324 shares acquired under the Company's ESPP.
F2 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 11, 2025.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.07 to $45.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.065 to $45.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The stock option is fully vested.
F6 In addition to the remaining options to purchase 70,600 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 339,440 shares of common stock, which options vest according to their terms.